P9623

Paroxetine hydrochloride hemihydrate

≥98% (HPLC), powder, serotonin reuptake inhibitor

• Synonyme(s) : Paroxetine HCl, (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride hemihydrate
• Formule empirique (notation de Hill) : C₁₉H₂₀FNO₃ · HCl · .5 H₂O
• Numéro CAS: 110429-35-1
• Poids moléculaire : 374.83
• UNSPSC Code: 12352200
• PubChem Substance ID: 24278249
• NACRES: NA.77
• MDL number: MFCD03658863
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Propriétés

• Nom du produit: Paroxetine hydrochloride hemihydrate, ≥98% (HPLC), powder
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white
• originator: GlaxoSmithKline
• SMILES string: O.Cl[H].Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3
• InChI: 1S/C19H20FNO3.ClH.H2O/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;;/h1-6,9,14,17,21H,7-8,10-12H2;1H;1H2/t14-,17-;;/m0../s1
• InChI key: QRQSGFFISBKLMZ-YHOFXEKLSA-N
• Gene Information: human ... SLC6A4(6532)

Description

Application

Paroxetine hydrochloride hemihydrate has been used: as an antidepressant to study its effects on neural stem cells (NSCs) from embryonic rat hippocampus in vitro; as a CYP 2D6 inhibitor to study its effects on the in vitro production by human recombinant CYP 2D6 of the phenolic metabolites; as an antidepressant to study its effects on the expression of pituitary adenylate cyclase activating polypeptide (PACAP), its receptors and brain-derived neurotrophic factor (BDNF) in rat primary hippocampal neurons

Biochem/physiol Actions

Paroxetine hydrochloride hemihydrate is one of the most potent and selective of the selective serotonin reuptake inhibitors (SSRI); antidepressant

Selective serotonin reuptake inhibitor; antidepressant

Paroxetine is a phenylpiperidine derivative. It has the ability to cross placenta. Paroxetine is known to increase the risk of congenital cardiac malformations. It might be useful in hormone replacement therapy for treating vasomotor symptoms during menopause. It is known to ameliorate the effects of panic disorder, obsessive‐compulsive disorder and social phobia.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold with the permission of GlaxoSmithKline

Informations sur la sécurité

• pictograms: GHS07,GHS09
• signalword: Warning
• hcodes: H302,H317,H319,H335,H410
• pcodes: P261 - P273 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Sens. 1 - STOT SE 3
• target_organs: Respiratory system
• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves